BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31729195)

  • 1. What impact could DMPA use have had in South Africa and how might its continued use affect the future of the HIV epidemic?
    Beacroft L; Smith JA; Hallett TB
    J Int AIDS Soc; 2019 Nov; 22(11):e25414. PubMed ID: 31729195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
    Smith JA; Beacroft L; Abdullah F; Buthelezi B; Makua M; Morroni C; Ramjee G; Velasquez C; Hallett TB
    J Int AIDS Soc; 2020 Oct; 23(10):e25620. PubMed ID: 33030312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
    Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
    Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies.
    Jain AK
    Contraception; 2012 Dec; 86(6):645-52. PubMed ID: 22541635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.
    Heffron R; Parikh UM; Penrose KJ; Mugo N; Donnell D; Celum C; Mellors JW; Baeten JM;
    AIDS Behav; 2017 Jul; 21(7):2173-2179. PubMed ID: 27699594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.
    Morrison CS; Chen PL; Kwok C; Baeten JM; Brown J; Crook AM; Van Damme L; Delany-Moretlwe S; Francis SC; Friedland BA; Hayes RJ; Heffron R; Kapiga S; Karim QA; Karpoff S; Kaul R; McClelland RS; McCormack S; McGrath N; Myer L; Rees H; van der Straten A; Watson-Jones D; van de Wijgert JH; Stalter R; Low N
    PLoS Med; 2015 Jan; 12(1):e1001778. PubMed ID: 25612136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda.
    Grabowski MK; Gray RH; Makumbi F; Kagaayi J; Redd AD; Kigozi G; Reynolds SJ; Nalugoda F; Lutalo T; Wawer MJ; Serwadda D; Quinn TC; Tobian AAR
    Lancet Glob Health; 2015 Aug; 3(8):e478-e486. PubMed ID: 26094162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Cervical CD4
    Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
    AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
    Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.
    Hapgood JP
    AIDS Res Hum Retroviruses; 2020 May; 36(5):357-366. PubMed ID: 31797677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
    Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
    AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
    Chinula L; Nelson JAE; Wiener J; Tang JH; Hurst S; Tegha G; Msika A; Ellington S; Hosseinipour MC; Mataya R; Haddad LB; Kourtis AP
    Contraception; 2018 Sep; 98(3):193-198. PubMed ID: 29746813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
    Bunjun R; Ramla TF; Jaumdally SZ; Noël-Romas L; Ayele H; Brown BP; Gamieldien H; Harryparsad R; Dabee S; Nair G; Onono M; Palanee-Phillips T; Scoville CW; Heller KB; Baeten JM; Bosinger SE; Burgener A; Passmore JS; Jaspan H; Heffron R
    Clin Infect Dis; 2022 Nov; 75(11):2000-2011. PubMed ID: 35941737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.
    Crook AM; Ford D; Gafos M; Hayes R; Kamali A; Kapiga S; Nunn A; Chisembele M; Ramjee G; Rees H; McCormack S
    Hum Reprod; 2014 Aug; 29(8):1810-7. PubMed ID: 24838704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.
    Zalenskaya IA; Chandra N; Yousefieh N; Fang X; Adedipe OE; Jackson SS; Anderson SM; Mauck CK; Schwartz JL; Thurman AR; Doncel GF
    J Clin Invest; 2018 Oct; 128(10):4622-4638. PubMed ID: 30222141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk.
    Butler K; Ritter JM; Ellis S; Morris MR; Hanson DL; McNicholl JM; Kersh EN
    J Acquir Immune Defic Syndr; 2016 Aug; 72(4):363-71. PubMed ID: 27355414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.
    Hofmeyr GJ; Singata-Madliki M; Lawrie TA; Bergel E; Temmerman M
    Reprod Health; 2016 Apr; 13():42. PubMed ID: 27091008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal contraception and the risk of HIV acquisition among women in South Africa.
    Morrison CS; Skoler-Karpoff S; Kwok C; Chen PL; van de Wijgert J; Gehret-Plagianos M; Patel S; Ahmed K; Ramjee G; Friedland B; Lahteenmaki P
    AIDS; 2012 Feb; 26(4):497-504. PubMed ID: 22156973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.